the need to incorporate disease-modifying drugs in lower-risk mds
Published 1 year ago • 82 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
2:42
hot topics in mpns: disease-modifying drugs, sequencing jak inhibitors and management of bp-mpns
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
0:59
hdxsim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in scd
-
2:13
exciting agents and treatment approaches emerging in the field of myelofibrosis
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
1:52
safety and efficacy of idasanutlin in pv
-
9:25
mgus diagnosis: a step-by-step approach
-
1:46:07
hematology lecture
-
6:24
indiko biochemistry analyzer demonstration
-
2:55
current and emerging treatments for mf: an update from ash 2023
-
1:30
advancements in prognostication tools in mpns in recent years
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:23
developing a pro collection tool for patients with scd: key themes which are important to patients
-
3:49
the patient burden of illness and unmet needs in scd & highlights from eha 2024
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
2:41
an overview of the latest advances in hematology
-
3:36
the genetic landscape of mds: how this is improving & impacting the development of therapies
-
2:12
barriers to the implementation and standardization of ai in the clinic
-
3:33
the growing role of machine learning in hematological oncology
-
4:20
therapy-related all: etiology, prognosis, and treatment